Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Other Non-Current Liabilities: 2017-2019

Historic Other Non-Current Liabilities for Cidara Therapeutics (CDTX) over the last 2 years, with Mar 2019 value amounting to $700,000.

  • Cidara Therapeutics' Other Non-Current Liabilities was N/A to $700,000 in Q1 2019 from the same period last year, while for Mar 2019 it was $700,000, marking a year-over-year change of. This contributed to the annual value of $411,000 for FY2018, which is N/A change from last year.
  • Per Cidara Therapeutics' latest filing, its Other Non-Current Liabilities stood at $700,000 for Q1 2019, which was up 70.32% from $411,000 recorded in Q4 2018.
  • In the past 5 years, Cidara Therapeutics' Other Non-Current Liabilities registered a high of $700,000 during Q1 2019, and its lowest value of $42,000 during Q2 2018.
  • For the 3-year period, Cidara Therapeutics' Other Non-Current Liabilities averaged around $203,143, with its median value being $71,000 (2017).
  • Over the last 5 years, Cidara Therapeutics' Other Non-Current Liabilities had its largest YoY gain of 1.64% in 2018, and its largest YoY loss of 40.85% in 2018.
  • Over the past 3 years, Cidara Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $61,000 in 2017, then increased by 1.64% to $411,000 in 2018, then reached $700,000 in 2019.
  • Its Other Non-Current Liabilities was $700,000 in Q1 2019, compared to $411,000 in Q4 2018 and $62,000 in Q3 2018.